Plasmin and the plasminogen activator system in health and disease

Extracellular Matrix: Pathobiology and Signaling

Volumn , Issue , 2012, Pages 261-290

  Svineng, Gunbjørg ^a   Magnussen, Synnøve ^a   Hadler Olsen, Elin ^a  

^a UNIVERSITY OF TROMSØ   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84904312914     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (246)

1. Aguirre-Ghiso, J. A., Liu, D., Mignatti, A., Kovalski, K., and Ossowski, L. (2001). Urokinase receptor and fibronectin regulate the ERK(MAPK) to p38(MAPK) activity ratios that determine carcinoma cell proliferation or dormancy in vivo. Mol Biol Cell 12, 863-879.
2. Ahn, J. H., Lee, H. J., Lee, E. K., et al. (2011). Antiangiogenic kringles derived from human plasminogen and apolipoprotein(a) inhibit fibrinolysis through a mechanism that requires a functional lysine-binding site. Biol Chem 392, 347-356.
3. Almasi, C. E., Christensen, I. J., Hoyer-Hansen, G., et al. (2011). Urokinase receptor forms in serum from non-small cell lung cancer patients: relation to prognosis. Lung Cancer 74, 510-515.
4. Almasi, C. E., Hoyer-Hansen, G., Christensen, I. J., Dano, K., and Pappot, H. (2005). Prognostic impact of liberated domain I of the urokinase plasminogen activator receptor in squamous cell lung cancer tissue. Lung Cancer 48, 349-355.
5. An, S. S., Carreno, C., Marti, D. N., Schaller, J., Albericio, F., and Llinas, M. (1998a). Lysine-50 is a likely site for anchoring the plasminogen N-terminal peptide to lysine-binding kringles. Protein Sci 7, 1960-1969.
6. An, S. S., Marti, D. N., Carreno, C., Albericio, F., Schaller, J., and Llinas, M. (1998b). Structural/functional properties of the Glu1-HSer57 N-terminal fragment of human plasminogen: conformational characterization and interaction with kringle domains. Protein Sci 7, 1947-1959.
7. Andolfo, A., English, W. R., Resnati, M., Murphy, G., Blasi, F., and Sidenius, N. (2002). Metalloproteases cleave the urokinase-type plasminogen activator receptor in the D1-D2 linker region and expose epitopes not present in the intact soluble receptor. Thromb Haemost 88, 298-306.
8. Andreasen, P. A., Kjoller, L., Christensen, L., and Duffy, M. J. (1997). The urokinase-type plasminogen activator system in cancer metastasis: a review. Int J Cancer 72, 1-22.
9. Andronicos, N. M., Chen, E. I., Baik, N., et al. (2010). Proteomics-based discovery of a novel, structurally unique, and developmentally regulated plasminogen receptor, Plg-RKT, a major regulator of cell surface plasminogen activation. Blood 115, 1319-1330.
10. Andronicos, N. M., and Ranson, M. (2001). The topology of plasminogen binding and activation on the surface of human breast cancer cells. Br J Cancer 85, 909-916.
11. Astedt, B., Lecander, I., Brodin, T., Lundblad, A., and Low, K. (1985). Purification of a specific placental plasminogen activator inhibitor by monoclonal antibody and its complex formation with plasminogen activator. Thromb Haemost 53, 122-125.
12. Bajou, K., Noel, A., Gerard, R. D., et al. (1998). Absence of host plasminogen activator inhibitor 1 prevents cancer invasion and vascularization. Nat Med 4, 923-928.
13. Baramova, E. N., Bajou, K., Remacle, A., et al. (1997). Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation. FEBS Lett 405, 157-162.
14. Barinka, C., Parry, G., Callahan, J., et al. (2006). Structural basis of interaction between urokinase-type plasminogen activator and its receptor. J Mol Biol 363, 482-495.
15. Beaufort, N., Debela, M., Creutzburg, S., et al. (2006). Interplay of human tissue kallikrein 4 (hK4) with the plasminogen activation system: hK4 regulates the structure and functions of the urokinase-type plasminogen activator receptor (uPAR). Biol Chem 387, 217-222.
16. Benvenuti, S., and Comoglio, P. M. (2007). The MET receptor tyrosine kinase in invasion and metastasis. J Cell Physiol 213, 316-325.
17. Blasi, F., and Carmeliet, P. (2002). uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3, 932-943.
18. Blasi, F., and Sidenius, N. (2010). The urokinase receptor: focused cell surface proteolysis, cell adhesion and signaling. FEBS Lett 584, 1923-1930.
19. Borza, D. B., Shipulina, N. V., and Morgan, W. T. (2004). Effects of histidine-proline-rich glycoprotein on plasminogen activation in solution and on surfaces. Blood Coagul Fibrinolysis 15, 663-672.
20. Brauer, R., Beck, I. M., Roderfeld, M., Roeb, E., and Sedlacek, R. (2011). Matrix metalloproteinase-19 inhibits growth of endothelial cells by generating angiostatin-like fragments from plasminogen. BMC Biochem 12, 38.
21. Brunner, G., Simon, M. M., and Kramer, M. D. (1990). Activation of pro-urokinase by the human T cell-associated serine proteinase HuTSP-1. FEBS Lett 260, 141-144.
22. Bugge, T. H., Flick, M. J., Daugherty, C. C., and Degen, J. L. (1995). Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 9, 794-807.
23. Cao, R., Wu, H. L., Veitonmaki, N., et al. (1999). Suppression of angiogenesis and tumor growth by the inhibitor K1-5 generated by plasmin-mediated proteolysis. Proc Natl Acad Sci U S A 96, 5728-5733.
24. Cao, Y., Chen, A., An, S. S., Ji, R. W., Davidson, D., and Llinas, M. (1997). Kringle 5 of plasminogen is a novel inhibitor of endothelial cell growth. J Biol Chem 272, 22924-22928.
25. Cao, Y., Veitonmaki, N., Keough, K., Cheng, H., Lee, L. S., and Zurakowski, D. (2000). Elevated levels of urine angiostatin and plasminogen/plasmin in cancer patients. Int J Mol Med 5, 547-551.
26. Cao, Y., and Xue, L. (2004). Angiostatin. Semin Thromb Hemost 30, 83-93.
27. Capello, M., Ferri-Borgogno, S., Cappello, P., and Novelli, F. (2011). A-Enolase: a promising therapeutic and diagnostic tumor target. FEBS J 278, 1064-1074.
28. Cesarman-Maus, G., and Hajjar, K. A. (2005). Molecular mechanisms of fibrinolysis. Br J Haematol 129, 307-321.
29. Chain, D., Kreizman, T., Shapira, H., and Shaltiel, S. (1991). Plasmin cleavage of vitronectin. Identification of the site and consequent attenuation in binding plasminogen activator inhibitor-1. FEBS Lett 285, 251-256.
30. Choi, K. S., Fogg, D. K., Yoon, C. S., and Waisman, D. M. (2003). p11 regulates extracellular plasmin production and invasiveness of HT1080 fibrosarcoma cells. FASEB J 17, 235-246.
31. Christensen, B., Schack, L., Klaning, E., and Sorensen, E. S. (2010). Osteopontin is cleaved at multiple sites close to its integrin-binding motifs in milk and is a novel substrate for plasmin and cathepsin D. J Biol Chem 285, 7929-7937.
32. Claesson-Welsh, L., Welsh, M., Ito, N., et al. (1998). Angiostatin induces endothelial cell apoptosis and activation of focal adhesion kinase independently of the integrin-binding motif RGD. Proc Natl Acad Sci U S A 95, 5579-5583.
33. Cockell, C. S., Marshall, J. M., Dawson, K. M., Cederholm-Williams, S. A., and Ponting, C. P. (1998). Evidence that the conformation of unliganded human plasminogen is maintained via an intramolecular interaction between the lysine-binding site of kringle 5 and the Nterminal peptide. Biochem J 333 ( Pt 1), 99-105.
34. Cornelius, L. A., Nehring, L. C., Harding, E., et al. (1998). Matrix metalloproteinases generate angiostatin: effects on neovascularization. J Immunol 161, 6845-6852.
35. Coughlin, P. B. (2005). Antiplasmin: the forgotten serpin? FEBS J 272, 4852-4857.
36. Croucher, D. R., Saunders, D. N., Lobov, S., and Ranson, M. (2008). Revisiting the biological roles of PAI2 (SERPINB2) in cancer. Nat Rev Cancer 8, 535-545.
37. Cubellis, M. V., Wun, T. C., and Blasi, F. (1990). Receptor-mediated internalization and degradation of urokinase is caused by its specific inhibitor PAI-1. EMBO J 9, 1079-1085.
38. Czekay, R. P., Kuemmel, T. A., Orlando, R. A., and Farquhar, M. G. (2001). Direct binding of occupied urokinase receptor (uPAR) to LDL receptor-related protein is required for endocytosis of uPAR and regulation of cell surface urokinase activity. Mol Biol Cell 12, 1467-1479.
39. Czekay, R. P., Wilkins-Port, C. E., Higgins, S. P., et al. (2011). PAI-1: an integrator of cell signaling and migration. Int J Cell Biol 2011, 562481.
40. Dallas, S. L., Miyazono, K., Skerry, T. M., Mundy, G. R., and Bonewald, L. F. (1995). Dual role for the latent transforming growth factor-beta binding protein in storage of latent TGF-beta in the extracellular matrix and as a structural matrix protein. J Cell Biol 131, 539-549.
41. Dallas, S. L., Rosser, J. L., Mundy, G. R., and Bonewald, L. F. (2002). Proteolysis of latent transforming growth factor-beta (TGF-beta )-binding protein-1 by osteoclasts. A cellular mechanism for release of TGF-beta from bone matrix. J Biol Chem 277, 21352-21360.
42. Dano, K., Andreasen, P. A., Grondahl-Hansen, J., Kristensen, P., Nielsen, L. S., and Skriver, L. (1985). Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res 44, 139-266.
43. Dano, K., Behrendt, N., Hoyer-Hansen, G., et al. (2005). Plasminogen activation and cancer. Thromb Haemost 93, 676-681.
44. Dano, K., Romer, J., Nielsen, B. S., et al. (1999). Cancer invasion and tissue remodelingcooperation of protease systems and cell types. APMIS 107, 120-127.
45. Das, R., Burke, T., and Plow, E. F. (2007). Histone H2B as a functionally important plasminogen receptor on macrophages. Blood 1 10, 3763-3772.
46. Dass, K., Ahmad, A., Azmi, A. S., Sarkar, S. H., and Sarkar, F. H. (2008). Evolving role of uPA/ uPAR system in human cancers. Cancer Treat Rev 34, 122-136.
47. Dong, Z., Kumar, R., Yang, X., and Fidler, I. J. (1997). Macrophage-derived metalloelastase is responsible for the generation of angiostatin in Lewis lung carcinoma. Cell 88, 801-810.
48. Dudani, A. K., and Ganz, P. R. (1996). Endothelial cell surface actin serves as a binding site for plasminogen, tissue plasminogen activator and lipoprotein(a). Br J Haematol 95, 168-178.
49. Eeckhout, Y., and Vaes, G. (1977). Further studies on the activation of procollagenase, the latent precursor of bone collagenase. Effects of lysosomal cathepsin B, plasmin and kallikrein, and spontaneous activation. Biochem J 166, 21-31.
50. Engelholm, L. H., Ingvarsen, S., Jurgensen, H. J., et al. (2009). The collagen receptor uPARAP/ Endo180. Front Biosci 14, 2103-2114.
51. Espana, F., Estelles, A., Fernandez, P. J., Gilabert, J., Sanchez-Cuenca, J., and Griffin, J. H. (1993). Evidence for the regulation of urokinase and tissue type plasminogen activators by the serpin, protein C inhibitor, in semen and blood plasma. Thromb Haemost 70, 989-994.
52. Estelles, A., Gilabert, J., Aznar, J., Loskutoff, D. J., and Schleef, R. R. (1989). Changes in the plasma levels of type 1 and type 2 plasminogen activator inhibitors in normal pregnancy and in patients with severe preeclampsia. Blood 74, 1332-1338.
53. Eugen-Olsen, J., Andersen, O., Linneberg, A., et al. (2010). Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Int Med 268, 296-308.
54. Fabbro, S., Schaller, K., and Seeds, N. W. (2011). Amyloid-beta levels are significantly reduced and spatial memory defects are rescued in a novel neuroserpin-deficient Alzheimer's disease transgenic mouse model. J Neurochem 118, 928-938.
55. Falcone, D. J., Khan, K. M., Layne, T., and Fernandes, L. (1998). Macrophage formation of angiostatin during inflammation. A byproduct of the activation of plasminogen. J Biol Chem 273, 31480-31485.
56. Foekens, J. A., Schmitt, M., van Putten, W. L., et al. (1994). Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol 12, 1648-1658.
57. Folkman, J. (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82, 4-6.
58. Fosang, A. J., Last, K., Fujii, Y., Seiki, M., and Okada, Y. (1998). Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett 430, 186-190.
59. Frank, P. S., Douglas, J. T., Locher, M., Llinas, M., and Schaller, J. (2003). Structural/functional characterization of the alpha 2-plasmin inhibitor C-terminal peptide. Biochemistry 42, 1078-1085.
60. Frenette, G., Tremblay, R. R., Lazure, C., and Dube, J. Y. (1997). Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. Int J Cancer 71, 897-899.
61. Galimi, F., Cottone, E., Vigna, E., et al. (2001). Hepatocyte growth factor is a regulator of monocyte-macrophage function. J Immunol 166, 1241-1247.
62. Gately, S., Twardowski, P., Stack, M. S., et al. (1997). The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA 94, 10868-10872.
63. Gebbink, M. F. (2011). Tissue-type plasminogen activator-mediated plasminogen activation and contact activation, implications in and beyond haemostasis. J Thromb Haemost 9 (Suppl. 1), 174-181.
64. Gold, L. I., Rostagno, A., Frangione, B., and Passalaris, T. (1992). Localization of the cleavage sites on fibronectin following digestion by urokinase. J Cell Biochem 50, 441-452.
65. Goldberg, G. I., Strongin, A., Collier, I. E., Genrich, L. T., and Marmer, B. L. (1992). Interaction of 92-kDa type IV collagenase with the tissue inhibitor of metalloproteinases prevents dimerization, complex formation with interstitial collagenase, and activation of the proenzyme with stromelysin. J Biol Chem 267, 4583-4591.
66. Goldfinger, L. E., Stack, M. S., and Jones, J. C. (1998). Processing of laminin-5 and its functional consequences: role of plasmin and tissue-type plasminogen activator. J Cell Biol 141, 255-265.
67. Goretzki, L., Schmitt, M., Mann, K., et al. (1992). Effective activation of the proenzyme form of the urokinase-type plasminogen activator (pro-uPA) by the cysteine protease cathepsin L. FEBS Lett 297, 112-118.
68. Grondahl-Hansen, J., Christensen, I. J., Rosenquist, C., et al. (1993). High levels of urokinasetype plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res 53, 2513-2521.
69. Grondahl-Hansen, J., Peters, H. A., van Putten, W. L., et al. (1995). Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1, 1079-1087.
70. Gutierrez, L. S., Schulman, A., Brito-Robinson, T., Noria, F., Ploplis, V. A., and Castellino, F. J. (2000). Tumor development is retarded in mice lacking the gene for urokinase-type plasminogen activator or its inhibitor, plasminogen activator inhibitor-1. Cancer Res 60, 5839-5847.
71. Hajjar, K. A., Harpel, P. C., Jaffe, E. A., and Nachman, R. L. (1986). Binding of plasminogen to cultured human endothelial cells. J Biol Chem 261, 11656-11662.
72. Hall, S. W., Humphries, J. E., and Gonias, S. L. (1991). Inhibition of cell surface receptor-bound plasmin by alpha 2-antiplasmin and alpha 2-macroglobulin. J Biol Chem 266, 12329-12336.
73. Han, J., Baik, N., Kim, K. H., et al. (2011). Monoclonal antibodies detect receptor-induced binding sites in Glu-plasminogen. Blood 118, 1653-1662.
74. Heidtmann, H. H., Nettelbeck, D. M., Mingels, A., Jager, R., Welker, H. G., and Kontermann, R. E. (1999). Generation of angiostatin-like fragments from plasminogen by prostate-specific antigen. Br J Cancer 81, 1269-1273.
75. Hekman, C. M., and Loskutoff, D. J. (1985). Endothelial cells produce a latent inhibitor of plasminogen activators that can be activated by denaturants. J Biol Chem 260, 11581-11587.
76. Hembrough, T. A., Kralovich, K. R., Li, L., and Gonias, S. L. (1996). Cytokeratin 8 released by breast carcinoma cells in vitro binds plasminogen and tissue-type plasminogen activator and promotes plasminogen activation. Biochem J 317 (Pt 3), 763-769.
77. Herz, J., and Strickland, D. K. (2001). LRP: a multifunctional scavenger and signaling receptor. J Clin Invest 108, 779-784.
78. Hildenbrand, R., Allgayer, H., Marx, A., and Stroebel, P. (2010). Modulators of the urokinasetype plasminogen activation system for cancer. Expert opinion on investigational drugs 19, 641-652.
79. Holmes, W. E., Nelles, L., Lijnen, H. R., and Collen, D. (1987). Primary structure of human alpha 2-antiplasmin, a serine protease inhibitor (serpin). J Biol Chem 262, 1659-1664.
80. Holmgren, L., O'Reilly, M. S., and Folkman, J. (1995). Dormancy of micrometastases: balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat Med 1, 149-153.
81. Ho-Tin-Noe, B., Rojas, G., Vranckx, R., Lijnen, H. R., and Angles-Cano, E. (2005). Functional hierarchy of plasminogen kringles 1 and 4 in fibrinolysis and plasmin-induced cell detachment and apoptosis. FEBS J 272, 3387-3400.
82. Hoyer-Hansen, G., Behrendt, N., Ploug, M., Dano, K., and Preissner, K. T. (1997). The intact urokinase receptor is required for efficient vitronectin binding: receptor cleavage prevents ligand interaction. FEBS Lett 420, 79-85.
83. Hoyer-Hansen, G., and Lund, I. K. (2007). Urokinase receptor variants in tissue and body fluids. Adv Clin Chem 44, 65-102.
84. Hu, G. F., Strydom, D. J., Fett, J. W., Riordan, J. F., and Vallee, B. L. (1993). Actin is a binding protein for angiogenin. Proc Natl Acad Sci U S A 90, 1217-1221.
85. Hu, X. W., Duan, H. F., Gao, L. H., et al. (2008). Inhibition of tumor growth and metastasis by ATF-Fc, an engineered antibody targeting urokinase receptor. Cancer Biol Ther 7, 651-659.
86. Huai, Q., Mazar, A. P., Kuo, A., et al. (2006). Structure of human urokinase plasminogen activator in complex with its receptor. Science 311, 656-659.
87. Huai, Q., Zhou, A., Lin, L., et al. (2008). Crystal structures of two human vitronectin, urokinase and urokinase receptor complexes. Nat Struct Mol Biol 15, 422-423.
88. Hundsdorfer, B., Zeilhofer, H. F., Bock, K. P., et al. (2005). Tumour-associated urokinase-type plasminogen activator (uPA) and its inhibitor PAI-1 in normal and neoplastic tissues of patients with squamous cell cancer of the oral cavity - clinical relevance and prognostic value. J Craniomaxillofac Surg 33, 191-196.
89. Huttunen, R., Syrjanen, J., Vuento, R., et al. (2011). Plasma level of soluble urokinase-type plasminogen activator receptor as a predictor of disease severity and case fatality in patients with bacteraemia: a prospective cohort study. J Int Med 270, 32-40.
90. Hynes, R. O. (1992). Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69, 11-25.
91. Ichinose, A., Fujikawa, K., and Suyama, T. (1986). The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. J Biol Chem 261, 3486-3489.
92. Jacobsen, J. S., Comery, T. A., Martone, R. L., et al. (2008). Enhanced clearance of Abeta in brain by sustaining the plasmin proteolysis cascade. Proc Natl Acad Sci U S A 105, 8754-8759.
93. Jenkins, G. (2008). The role of proteases in transforming growth factor-beta activation. Int J Biochem Cell Biol 40, 1068-1078.
94. Ji, W. R., Barrientos, L. G., Llinas, M., et al. (1998a). Selective inhibition by kringle 5 of human plasminogen on endothelial cell migration, an important process in angiogenesis. Biochem Biophys Res Commun 247, 414-419.
95. Ji, W. R., Castellino, F. J., Chang, Y., et al. (1998b). Characterization of kringle domains of angiostatin as antagonists of endothelial cell migration, an important process in angiogenesis. FASEB J 12, 1731-1738.
96. Jiang, Q., Taupenot, L., Mahata, S. K., et al. (2001). Proteolytic cleavage of chromogranin A (CgA) by plasmin. Selective liberation of a specific bioactive CgA fragment that regulates catecholamine release. J Biol Chem 276, 25022-25029.
97. Jones, A. L., Hulett, M. D., Altin, J. G., Hogg, P., and Parish, C. R. (2004). Plasminogen is tethered with high affinity to the cell surface by the plasma protein, histidine-rich glycoprotein. J Biol Chem 279, 38267-38276.
98. Kassam, G., Kwon, M., Yoon, C. S., et al. (2001). Purification and characterization of A61. An angiostatin-like plasminogen fragment produced by plasmin autodigestion in the absence of sulfhydryl donors. J Biol Chem 276, 8924-8933.
99. Killer, M., Ladurner, G., Kunz, A. B., and Kraus, J. (2010). Current endovascular treatment of acute stroke and future aspects. Drug Discov Today 15, 640-647.
100. Kingston, I. B., Kingston, B. L., and Putnam, F. W. (1977). Chemical evidence that proteolytic cleavage causes the heterogeneity present in human ceruloplasmin preparations. Proc Natl Acad Sci U S A 74, 5377-5381.
101. Kinnby, B. (2002). The plasminogen activating system in periodontal health and disease. Biol Chem 383, 85-92.
102. Kjoller, L., and Hall, A. (2001). Rac mediates cytoskeletal rearrangements and increased cell motility induced by urokinase-type plasminogen activator receptor binding to vitronectin. J Cell Biol 152, 1145-1157.
103. Knauper, V., Will, H., Lopez-Otin, C., et al. (1996). Cellular mechanisms for human procol-lagenase-3 (MMP-13) activation. Evidence that MT1-MMP (MMP-14) and gelatinase a (MMP-2) are able to generate active enzyme. J Biol Chem 271, 17124-17131.
104. Kobayashi, H., Schmitt, M., Goretzki, L., et al. (1991). Cathepsin B efficiently activates the soluble and the tumor cell receptor-bound form of the proenzyme urokinase-type plasminogen activator (Pro-uPA). J Biol Chem 266, 5147-5152.
105. Koivunen, E., Huhtala, M. L., and Stenman, U. H. (1989). Human ovarian tumor-associated trypsin. Its purification and characterization from mucinous cyst fluid and identification as an activator of pro-urokinase. J Biol Chem 264, 14095-14099.
106. Koolwijk, P., Sidenius, N., Peters, E., et al. (2001). Proteolysis of the urokinase-type plasminogen activator receptor by metalloproteinase-12: implication for angiogenesis in fibrin matrices. Blood 97, 3123-3131.
107. Kristensen, T., Moestrup, S. K., Gliemann, J., Bendtsen, L., Sand, O., and Sottrup-Jensen, L. (1990). Evidence that the newly cloned low-density-lipoprotein receptor related protein (LRP) is the alpha 2-macroglobulin receptor. FEBS Lett 276, 151-155.
108. Kruithof, E. K., Vassalli, J. D., Schleuning, W. D., Mattaliano, R. J., and Bachmann, F. (1986). Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem 261, 11207-11213.
109. Kuhn, W., Pache, L., Schmalfeldt, B., et al. (1994). Urokinase (uPA) and PAI-1 predict survival in advanced ovarian cancer patients (FIGO III) after radical surgery and platinum-based chemotherapy. Gynecol Oncol 55, 401-409.
110. Kwon, M., Yoon, C. S., Fitzpatrick, S., et al. (2001). p22 is a novel plasminogen fragment with antiangiogenic activity. Biochemistry 40, 13246-13253.
111. Lalou, C., Sawamura, S., Segovia, B., Ogawa, Y., and Binoux, M. (1997). Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity. C R Acad Sci III 320, 621-628.
112. Lee, J. A., Cochran, B. J., Lobov, S., and Ranson, M. (2011a). Forty years later and the role of plasminogen activator inhibitor type 2/SERPINB2 is still an enigma. Semin Thromb Hemost 37, 395-407.
113. Lee, K. N., Jackson, K. W., Christiansen, V. J., Dolence, E. K., and McKee, P. A. (2011b). Enhancement of fibrinolysis by inhibiting enzymatic cleavage of precursor alpha2-antiplasmin. J Thromb Haemost 9, 987-996.
114. Lee, T. Y., Muschal, S., Pravda, E. A., Folkman, J., Abdollahi, A., and Javaherian, K. (2009). Angiostatin regulates the expression of antiangiogenic and proapoptotic pathways via targeted inhibition of mitochondrial proteins. Blood 114, 1987-1998.
115. Li, Y., and Cozzi, P. J. (2007). Targeting uPA/uPAR in prostate cancer. Cancer Treat Rev 33, 521-527.
116. Lighvani, S., Baik, N., Diggs, J. E., Khaldoyanidi, S., Parmer, R. J., and Miles, L. A. (2011). Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT.. Blood 1 18 (20), 5622-5630.
117. Lijnen, H. R. (2002). Matrix metalloproteinases and cellular fibrinolytic activity. Biochemistry (Mosc) 67, 92-98.
118. Lijnen, H. R., Ugwu, F., Bini, A., and Collen, D. (1998a). Generation of an angiostatin-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry 37, 4699-4702.
119. Lijnen, H. R., Van Hoef, B., and Collen, D. (2001). Inactivation of the serpin alpha (2)-antiplasmin by stromelysin-1. Biochim Biophys Acta 1547, 206-213.
120. Lijnen, H. R., Van Hoef, B., Lupu, F., Moons, L., Carmeliet, P., and Collen, D. (1998b). Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 18, 1035-1045.
121. Lim, Y. T., Sugiura, Y., Laug, W. E., Sun, B., Garcia, A., and DeClerck, Y. A. (1996). Independent regulation of matrix metalloproteinases and plasminogen activators in human fibrosarcoma cells. J Cell Physiol 167, 333-340.
122. Lindahl, T. L., Sigurdardottir, O., and Wiman, B. (1989). Stability of plasminogen activator inhibitor 1 (PAI-1). Thromb Haemost 62, 748-751.
123. Liu, D., Aguirre Ghiso, J., Estrada, Y., and Ossowski, L. (2002). EGFR is a transducer of the urokinase receptor initiated signal that is required for in vivo growth of a human carcinoma. Cancer Cell 1, 445-457.
124. Liu, Z., Li, N., Diaz, L. A., Shipley, M., Senior, R. M., and Werb, Z. (2005). Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 115, 879-887.
125. Llinas, P., Le Du, M. H., Gardsvoll, H., et al. (2005). Crystal structure of the human urokinase plasminogen activator receptor bound to an antagonist peptide. EMBO J 24, 1655-1663.
126. Loew, D., Perrault, C., Morales, M., et al. (2000). Proteolysis of the exodomain of recombinant protease-activated receptors: prediction of receptor activation or inactivation by MALDI mass spectrometry. Biochemistry 39, 10812-10822.
127. Lucas, R., Holmgren, L., Garcia, I., et al. (1998). Multiple forms of angiostatin induce apoptosis in endothelial cells. Blood 92, 4730-4741.
128. Luo, L. Y., Shan, S. J., Elliott, M. B., Soosaipillai, A., and Diamandis, E. P. (2006). Purification and characterization of human kallikrein 11, a candidate prostate and ovarian cancer biomarker, from seminal plasma. Clin Cancer Res 12, 742-750.
129. Lyons, R. M., Gentry, L. E., Purchio, A. F., and Moses, H. L. (1990). Mechanism of activation of latent recombinant transforming growth factor beta 1 by plasmin. J Cell Biol 1 10, 1361-1367.
130. Madsen, C. D., and Sidenius, N. (2008). The interaction between urokinase receptor and vitronectin in cell adhesion and signalling. Eur J Cell Biol 87, 617-629.
131. Madureira, P. A., Surette, A. P., Phipps, K. D., Taboski, M. A., Miller, V. A., and Waisman, D. M. (2011). The role of the annexin A2 heterotetramer in vascular fibrinolysis. Blood 118, 4789-4797.
132. Maggard, M. A., Catlin, E. A., Hudson, P. L., Donahoe, P. K., and MacLaughlin, D. T. (1996). Reduction of epidermal growth factor receptor phosphorylation by activated Mullerian inhibiting substance is vanadate-sensitive. Metabolism 45, 190-195.
133. Marcotte, P. A., Kozan, I. M., Dorwin, S. A., and Ryan, J. M. (1992). The matrix metalloproteinase pump-1 catalyzes formation of low molecular weight (pro)urokinase in cultures of normal human kidney cells. J Biol Chem 267, 13803-13806.
134. Mars, W. M., Zarnegar, R., and Michalopoulos, G. K. (1993). Activation of hepatocyte growth factor by the plasminogen activators uPA and tPA. Am J Pathol 143, 949-958.
135. Mason, S. D., and Joyce, J. A. (2011). Proteolytic networks in cancer. Trends Cell Biol 21, 228-237.
136. Mayer, U., Mann, K., Timpl, R., and Murphy, G. (1993). Sites of nidogen cleavage by proteases involved in tissue homeostasis and remodelling. Eur J Biochem 217, 877-884.
137. Mazzieri, R., Masiero, L., Zanetta, L., et al. (1997). Control of type IV collagenase activity by components of the urokinase-plasmin system: a regulatory mechanism with cell-bound reactants. EMBO J 16, 2319-2332.
138. McColl, B. K., Baldwin, M. E., Roufail, S., et al. (2003). Plasmin activates the lymphangiogenic growth factors VEGF-C and VEGF-D. J Exp Med 198, 863-868.
139. McMahon, G. A., Petitclerc, E., Stefansson, S., et al. (2001). Plasminogen activator inhibitor-1 regulates tumor growth and angiogenesis. J Biol Chem 276, 33964-33968.
140. Mehta, R., and Shapiro, A. D. (2008). Plasminogen deficiency. Haemophilia 14, 1261-1268.
141. Mignatti, P., and Rifkin, D. B. (1993). Biology and biochemistry of proteinases in tumor invasion. Physiol Rev 73, 161-195.
142. Miles, L. A., Castellino, F. J., and Gong, Y. (2003). Critical role for conversion of gluplasminogen to Lys-plasminogen for optimal stimulation of plasminogen activation on cell surfaces. Trends Cardiovasc Med 13, 21-30.
143. Miles, L. A., Dahlberg, C. M., Plescia, J., Felez, J., Kato, K., and Plow, E. F. (1991). Role of cell-surface lysines in plasminogen binding to cells: identification of alpha-enolase as a candidate plasminogen receptor. Biochemistry 30, 1682-1691.
144. Miranda, E., and Lomas, D. A. (2006). Neuroserpin: a serpin to think about. Cell Mol Life Sci 63, 709-722.
145. Monea, S., Lehti, K., Keski-Oja, J., and Mignatti, P. (2002). Plasmin activates pro-matrix metalloproteinase-2 with a membrane-type 1 matrix metalloproteinase-dependent mechanism. J Cell Physiol 192, 160-170.
146. Moran, P., Li, W., Fan, B., Vij, R., Eigenbrot, C., and Kirchhofer, D. (2006). Pro-urokinasetype plasminogen activator is a substrate for hepsin. J Biol Chem 281, 30439-30446.
147. Morikawa, W., Yamamoto, K., Ishikawa, S., et al. (2000). Angiostatin generation by cathepsin D secreted by human prostate carcinoma cells. J Biol Chem 275, 38912-38920.
148. Moser, T. L., Stack, M. S., Asplin, I., et al. (1999). Angiostatin binds ATP synthase on the surface of human endothelial cells. Proc Natl Acad Sci U S A 96, 2811-2816.
149. Mosesson, M. W. (2005). Fibrinogen and fibrin structure and functions. J Thromb Haemost 3, 1894-1904.
150. Murphy, G., Stanton, H., Cowell, S., et al. (1999). Mechanisms for pro matrix metalloproteinase activation. APMIS 107, 38-44.
151. Myohanen, H., and Vaheri, A. (2004). Regulation and interactions in the activation of cell-associated plasminogen. Cell Mol Life Sci 61, 2840-2858.
152. Naldini, L., Tamagnone, L., Vigna, E., et al. (1992). Extracellular proteolytic cleavage by urokinase is required for activation of hepatocyte growth factor/scatter factor. EMBO J 11, 4825-4833.
153. Naumov, G. N., Akslen, L. A., and Folkman, J. (2006). Role of angiogenesis in human tumor dormancy: animal models of the angiogenic switch. Cell Cycle 5, 1779-1787.
154. Nayeem, N., Silletti, S., Yang, X., et al. (1999). A potential role for the plasmin(ogen) system in the posttranslational cleavage of the neural cell adhesion molecule L1. J Cell Sci 112 (Pt 24), 4739-4749.
155. Novak, J. F., Hayes, J. D., and Nishimoto, S. K. (1997). Plasmin-mediated proteolysis of osteocalcin. J Bone Miner Res 12, 1035-1042.
156. Nykjaer, A., Petersen, C. M., Moller, B., et al. (1992). Purified alpha 2-macroglobulin receptor/LDL receptor-related protein binds urokinase.plasminogen activator inhibitor type-1 complex. Evidence that the alpha 2-macroglobulin receptor mediates cellular degradation of urokinase receptor-bound complexes. J Biol Chem 267, 14543-14546.
157. O'Brien, P., and O'Connor, B. F. (2008). Seprase: an overview of an important matrix serine protease. Biochim Biophys Acta 1784, 1130-1145.
158. Ogura, Y., Matsunaga, Y., Nishiyama, T., and Amano, S. (2008). Plasmin induces degradation and dysfunction of laminin 332 (laminin 5) and impaired assembly of basement membrane at the dermal-epidermal junction. Br J Dermatol 159, 49-60.
159. Ohkura, N., Hagihara, Y., Yoshimura, T., Goto, Y., and Kato, H. (1998). Plasmin can reduce the function of human beta2 glycoprotein I by cleaving domain V into a nicked form. Blood 91, 4173-4179.
160. Okumura, Y., Sato, H., Seiki, M., and Kido, H. (1997). Proteolytic activation of the precursor of membrane type 1 matrix metalloproteinase by human plasmin. A possible cell surface activator. FEBS Lett 402, 181-184.
161. O'Reilly, M. S., Holmgren, L., Shing, Y., et al. (1994). Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 79, 315-328.
162. O'Reilly, M. S., Wiederschain, D., Stetler-Stevenson, W. G., Folkman, J., and Moses, M. A. (1999). Regulation of angiostatin production by matrix metalloproteinase-2 in a model of concomitant resistance. J Biol Chem 274, 29568-29571.
163. Ossowski, L., and Reich, E. (1983). Antibodies to plasminogen activator inhibit human tumor metastasis. Cell 35, 611-619.
164. Ostrowski, S. R., Shulman, C. E., Peshu, N., et al. (2007). Elevated plasma urokinase receptor predicts low birth weight in maternal malaria. Parasite Immunol 29, 37-46.
165. Owen, K. A., Qiu, D., Alves, J., et al. (2010). Pericellular activation of hepatocyte growth factor by the transmembrane serine proteases matriptase and hepsin, but not by the membrane-associated protease uPA. Biochem J 426, 219-228.
166. Patterson, B. C., and Sang, Q. A. (1997). Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B/type IV collagenase (MMP-9). J Biol Chem 272, 28823-28825.
167. Paulsson, M., Saladin, K., and Landwehr, R. (1988). Binding of Ca2+ influences susceptibility of laminin to proteolytic digestion and interactions between domain-specific laminin fragments. Eur J Biochem 177, 477-481.
168. Pedersen, H., Grondahl-Hansen, J., Francis, D., et al. (1994). Urokinase and plasminogen activator inhibitor type 1 in pulmonary adenocarcinoma. Cancer Res 54, 120-123.
169. Petersen, T. E., Martzen, M. R., Ichinose, A., and Davie, E. W. (1990). Characterization of the gene for human plasminogen, a key proenzyme in the fibrinolytic system. J Biol Chem 265, 6104-6111.
170. Phipps, K. D., Surette, A. P., O'Connell, P. A., and Waisman, D. M. (2011). Plasminogen receptor S100A10 is essential for the migration of tumor-promoting macrophages into tumor sites. Cancer Res 71, 6676-6683.
171. Plow, E. F., Herren, T., Redlitz, A., Miles, L. A., and Hoover-Plow, J. L. (1995). The cell biology of the plasminogen system. FASEB J 9, 939-945.
172. Ponting, C. P., Marshall, J. M., and Cederholm-Williams, S. A. (1992). Plasminogen: a structural review. Blood Coagul Fibrinolysis 3, 605-614.
173. Poon, I. K., Olsson, A. K., Hulett, M. D., and Parish, C. R. (2009). Regulation of histidine-rich glycoprotein (HRG) function via plasmin-mediated proteolytic cleavage. Biochem J 424, 27-37.
174. Poon, I. K., Patel, K. K., Davis, D. S., Parish, C. R., and Hulett, M. D. (2011). Histidine-rich glycoprotein: the Swiss army knife of mammalian plasma. Blood 117, 2093-2101.
175. Preissner, K. T., and Seiffert, D. (1998). Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thromb Res 89, 1-21.
176. Pryzdial, E. L., Lavigne, N., Dupuis, N., and Kessler, G. E. (1999). Plasmin converts factor X from coagulation zymogen to fibrinolysis cofactor. J Biol Chem 274, 8500-8505.
177. Pure, E. (2009). The road to integrative cancer therapies: emergence of a tumor-associated fibroblast protease as a potential therapeutic target in cancer. Expert Opin Ther Targets 13, 967-973.
178. Quagraine, M. O., Tan, F., Tamei, H., Erdos, E. G., and Skidgel, R. A. (2005). Plasmin alters the activity and quaternary structure of human plasma carboxypeptidase N. Biochem J 388, 81-91.
179. Ra, H. J., and Parks, W. C. (2007). Control of matrix metalloproteinase catalytic activity. Matrix Biol 26, 587-596.
180. Ramos-DeSimone, N., Hahn-Dantona, E., Sipley, J., Nagase, H., French, D. L., and Quigley, J. P. (1999). Activation of matrix metalloproteinase-9 (MMP-9) via a converging plasmin/ stromelysin-1 cascade enhances tumor cell invasion. J Biol Chem 274, 13066-13076.
181. Rasch, M. G., Lund, I. K., Almasi, C. E., and Hoyer-Hansen, G. (2008). Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 13, 6752-6762.
182. Rawlings, N. D., Barrett, A. J., and Bateman, A. (2010). MEROPS: the peptidase database. Nucleic Acids Res 38, D227-D233.
183. Ricciardelli, C., Sakko, A. J., Ween, M. P., Russell, D. L., and Horsfall, D. J. (2009). The biological role and regulation of versican levels in cancer. Cancer Metastasis Rev 28, 233-245.
184. Robbins, K. C., Summaria, L., Hsieh, B., and Shah, R. J. (1967). The peptide chains of human plasmin. Mechanism of activation of human plasminogen to plasmin. J Biol Chem 242, 2333-2342.
185. Ryan, M. H., Petrone, D., Nemeth, J. F., Barnathan, E., Bjorck, L., and Jordan, R. E. (2008). Proteolysis of purified IgGs by human and bacterial enzymes in vitro and the detection of specific proteolytic fragments of endogenous IgG in rheumatoid synovial fluid. Mol Immunol 45, 1837-1846.
186. Sasaki, T., Mann, K., Murphy, G., Chu, M. L., and Timpl, R. (1996). Different susceptibilities of fibulin-1 and fibulin-2 to cleavage by matrix metalloproteinases and other tissue proteases. Eur J Biochem 240, 427-434.
187. Saunders, W. B., Bayless, K. J., and Davis, G. E. (2005). MMP-1 activation by serine proteases and MMP-10 induces human capillary tubular network collapse and regression in 3D collagen matrices. J Cell Sci 118, 2325-2340.
188. Schaller, J., and Gerber, S. S. (2011). The plasmin-antiplasmin system: structural and functional aspects. Cell Mol Life Sci 68, 785-801.
189. Schaller, J., Nick, H., Rickli, E. E., Gillessen, D., Lergier, W., and Studer, R. O. (1982). Human low-molecular-weight urinary urokinase. Partial characterization and preliminary sequence data of the two polypeptide chains. Eur J Biochem 125, 251-257.
190. Schatteman, K. A., Goossens, F. J., Scharpe, S. S., and Hendriks, D. F. (2000). Proteolytic activation of purified human procarboxypeptidase U. Clin Chim Acta 292, 25-40.
191. Schmidt, A., Echtermeyer, F., Alozie, A., Brands, K., and Buddecke, E. (2005). Plasmin- and thrombin-accelerated shedding of syndecan-4 ectodomain generates cleavage sites at Lys (114)-Arg(115) and Lys(129)-Val(130) bonds. J Biol Chem 280, 34441-34446.
192. Schmitt, M., Kanayama, N., Henschen, A., et al. (1989). Elastase released from human granulocytes stimulated with N-formyl-chemotactic peptide prevents activation of tumor cell prourokinase (pro-uPA). FEBS Lett 255, 83-88.
193. Schroeck, F., Arroyo de Prada, N., Sperl, S., Schmitt, M., and Viktor, M. (2002). Interaction of plasminogen activator inhibitor type-1 (PAI-1) with vitronectin (Vn): mapping the binding sites on PAI-1 and Vn. Biol Chem 383, 1143-1149.
194. Seiffert, D., and Loskutoff, D. J. (1996). Type 1 plasminogen activator inhibitor induces multimerization of plasma vitronectin. A suggested mechanism for the generation of the tissue form of vitronectin in vivo. J Biol Chem 271, 29644-29651.
195. Shanmukhappa, K., Matte, U., Degen, J. L., and Bezerra, J. A. (2009). Plasmin-mediated proteolysis is required for hepatocyte growth factor activation during liver repair. J Biol Chem 284, 12917-12923.
196. Shi, Z., and Stack, M. S. (2007). Urinary-type plasminogen activator (uPA) and its receptor (uPAR) in squamous cell carcinoma of the oral cavity. Biochem J 407, 153-159.
197. Sier, C. F., Stephens, R., Bizik, J., et al. (1998). The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients. Cancer Res 58, 1843-1849.
198. Smith, H. W., Marra, P., and Marshall, C. J. (2008). uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180. J Cell Biol 182, 777-790.
199. Smith, H. W., and Marshall, C. J. (2010). Regulation of cell signalling by uPAR. Nat Rev Mol Cell Biol 11, 23-36.
200. Soff, G. A. (2000). Angiostatin and angiostatin-related proteins. Cancer Metastasis Rev 19, 97-107.
201. Soff, G. A., Sanderowitz, J., Gately, S., et al. (1995). Expression of plasminogen activator inhibitor type 1 by human prostate carcinoma cells inhibits primary tumor growth, tumor-associated angiogenesis, and metastasis to lung and liver in an athymic mouse model. J Clin Invest 96, 2593-2600.
202. Solberg, H., Ploug, M., Hoyer-Hansen, G., Nielsen, B. S., and Lund, L. R. (2001). The murine receptor for urokinase-type plasminogen activator is primarily expressed in tissues actively undergoing remodeling. J Histochem Cytochem 49, 237-246.
203. Solomayer, E. F., Diel, I. J., Wallwiener, D., et al. (1997). Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer. Br J Cancer 76, 812-818.
204. Sorio, C., Mafficini, A., Furlan, F., et al. (2011). Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 11, 448.
205. Sottrup-Jensen, L. (1989). Alpha-macroglobulins: structure, shape, and mechanism of proteinase complex formation. J Biol Chem 264, 11539-11542.
206. Sottrup-Jensen, L., Lonblad, P. B., Stepanik, T. M., Petersen, T. E., Magnusson, S., and Jornvall, H. (1981). Primary structure of the "bait" region for proteinases in alpha 2-macroglobulin. Nature of the complex. FEBS Lett 127, 167-173.
207. Spraggon, G., Phillips, C., Nowak, U. K., et al. (1995). The crystal structure of the catalytic domain of human urokinase-type plasminogen activator. Structure 3, 681-691.
208. Sprengers, E. D., and Kluft, C. (1987). Plasminogen activator inhibitors. Blood 69, 381-387.
209. Stack, M. S., Gately, S., Bafetti, L. M., Enghild, J. J., and Soff, G. A. (1999). Angiostatin inhibits endothelial and melanoma cellular invasion by blocking matrix-enhanced plasminogen activation. Biochem J 340 ( Pt 1), 77-84.
210. Stack, M. S., and Johnson, D. A. (1994). Human mast cell tryptase activates single-chain urinary-type plasminogen activator (pro-urokinase). J Biol Chem 269, 9416-9419.
211. Stefansson, S., Petitclerc, E., Wong, M. K., McMahon, G. A., Brooks, P. C., and Lawrence, D. A. (2001). Inhibition of angiogenesis in vivo by plasminogen activator inhibitor-1. J Biol Chem 276, 8135-8141.
212. Stefansson, S., Su, E. J., Ishigami, S., et al. (2007). The contributions of integrin affinity and integrin-cytoskeletal engagement in endothelial and smooth muscle cell adhesion to vitronectin. J Biol Chem 282, 15679-15689.
213. Steinberg, S. F. (2005). The cardiovascular actions of protease-activated receptors. Mol Pharmacol 67, 2-11.
214. Stephens, R. W., Nielsen, H. J., Christensen, I. J., et al. (1999). Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91, 869-874.
215. Stephens, R. W., Pollanen, J., Tapiovaara, H., et al. (1989). Activation of pro-urokinase and plasminogen on human sarcoma cells: a proteolytic system with surface-bound reactants. J Cell Biol 108, 1987-1995.
216. Stoppelli, M. P., Corti, A., Soffientini, A., Cassani, G., Blasi, F., and Assoian, R. K. (1985). Differentiation-enhanced binding of the amino-terminal fragment of human urokinase plasminogen activator to a specific receptor on U937 monocytes. Proc Natl Acad Sci USA 82, 4939-4943.
217. Surette, A. P., Madureira, P. A., Phipps, K. D., Miller, V. A., Svenningsson, P., and Waisman, D. M. (2011). Regulation of fibrinolysis by S100A10 in vivo. Blood 118, 3172-3181.
218. Taipale, J., Koli, K., and Keski-Oja, J. (1992). Release of transforming growth factor-beta 1 from the pericellular matrix of cultured fibroblasts and fibrosarcoma cells by plasmin and thrombin. J Biol Chem 267, 25378-25384.
219. Takada, A., Sugawara, Y., and Takada, Y. (1988). Degradation of Glu- and Lys-plasminogen by elastase in the presence or absence of tranexamic acid. Thromb Res 50, 285-294.
220. Takayama, T. K., McMullen, B. A., Nelson, P. S., Matsumura, M., and Fujikawa, K. (2001). Characterization of hK4 (prostase), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. Biochemistry 40, 15341-15348.
221. Tang, C. H., and Wei, Y. (2008). The urokinase receptor and integrins in cancer progression. Cell Mol Life Sci 65, 1916-1932.
222. Tang, H., Kerins, D. M., Hao, Q., Inagami, T., and Vaughan, D. E. (1998). The urokinase-type plasminogen activator receptor mediates tyrosine phosphorylation of focal adhesion proteins and activation of mitogen-activated protein kinase in cultured endothelial cells. J Biol Chem 273, 18268-18272.
223. Tarui, T., Miles, L. A., and Takada, Y. (2001). Specific interaction of angiostatin with integrin alpha(v)beta(3) in endothelial cells. J Biol Chem 276, 39562-39568.
224. Tjwa, M., Sidenius, N., Moura, R., et al. (2009). Membrane-anchored uPAR regulates the proliferation, marrow pool size, engraftment, and mobilization of mouse hematopoietic stem/ progenitor cells. J Clin Invest 119, 1008-1018.
225. Troyanovsky, B., Levchenko, T., Mansson, G., Matvijenko, O., and Holmgren, L. (2001). Angiomotin: an angiostatin binding protein that regulates endothelial cell migration and tube formation. J Cell Biol 152, 1247-1254.
226. Tsiftsoglou, S. A., Willis, A. C., Li, P., et al. (2005). The catalytically active serine protease domain of human complement factor I. Biochemistry 44, 6239-6249.
227. Tsuchida-Straeten, N., Ensslen, S., Schafer, C., et al. (2005). Enhanced blood coagulation and fibrinolysis in mice lacking histidine-rich glycoprotein (HRG). J Thromb Haemost 3, 865-872.
228. Tucker, H. M., Kihiko, M., Caldwell, J. N., et al. (2000). The plasmin system is induced by and degrades amyloid-beta aggregates. J Neurosci 20, 3937-3946.
229. Ulisse, S., Baldini, E., Sorrenti, S., and D'Armiento, M. (2009). The urokinase plasminogen activator system: a target for anti-cancer therapy. Curr Cancer Drug Targets 9, 32-71.
230. Vassalli, J. D., Baccino, D., and Belin, D. (1985). A cellular binding site for the Mr 55,000 form of the human plasminogen activator, urokinase. J Cell Biol 100, 86-92.
231. Vigna, E., Naldini, L., Tamagnone, L., et al. (1994). Hepatocyte growth factor and its receptor, the tyrosine kinase encoded by the c-MET proto-oncogene. Cell Mol Biol (Noisyle-grand) 40, 597-604.
232. Vincenza Carriero, M., Franco, P., Vocca, I., et al. (2009). Structure, function and antagonists of urokinase-type plasminogen activator. Front Biosci 14, 3782-3794.
233. Wahlberg, K., Hoyer-Hansen, G., and Casslen, B. (1998). Soluble receptor for urokinase plasminogen activator in both full-length and a cleaved form is present in high concentration in cystic fluid from ovarian cancer. Cancer Res 58, 3294-3298.
234. Wang, H., Doll, J. A., Jiang, K., et al. (2006). Differential binding of plasminogen, plasmin, and angiostatin4.5 to cell surface beta-actin: implications for cancer-mediated angiogenesis. Cancer Res 66, 7211-7215.
235. Wang, H., Schultz, R., Hong, J., Cundiff, D. L., Jiang, K., and Soff, G. A. (2004). Cell surface-dependent generation of angiostatin4.5. Cancer Res 64, 162-168.
236. Wei, C., Moller, C. C., Altintas, M. M., et al. (2008). Modification of kidney barrier function by the urokinase receptor. Nat Med 14, 55-63.
237. Wei, Y., Waltz, D. A., Rao, N., Drummond, R. J., Rosenberg, S., and Chapman, H. A. (1994). Identification of the urokinase receptor as an adhesion receptor for vitronectin. J Biol Chem 269, 32380-32388.
238. Westphal, J. R., Van't Hullenaar, R., Geurts-Moespot, A., et al. (2000). Angiostatin generation by human tumor cell lines: involvement of plasminogen activators. Int J Cancer 86, 760-767.
239. Wilhelm, O. G., Wilhelm, S., Escott, G. M., et al. (1999). Cellular glycosylphosphatidylinositolspecific phospholipase D regulates urokinase receptor shedding and cell surface expression. JCell Physiol 180, 225-235.
240. Wolf, B. B., Vasudevan, J., Henkin, J., and Gonias, S. L. (1993). Nerve growth factor-gamma activates soluble and receptor-bound single chain urokinase-type plasminogen activator. J Biol Chem 268, 16327-16331.
241. Wygrecka, M., Marsh, L. M., Morty, R. E., et al. (2009). Enolase-1 promotes plasminogenmediated recruitment of monocytes to the acutely inflamed lung. Blood 1 13, 5588-5598.
242. Yamaguchi, Y., Du, X. Y., Zhao, L., Morser, J., and Leung, L. L. (2011). Proteolytic cleavage of chemerin protein is necessary for activation to the active form, Chem157S, which functions as a signaling molecule in glioblastoma. J Biol Chem 286, 39510-39519.
243. Yilmaz, G., Mentese, A., Kaya, S., Uzun, A., Karahan, S. C., and Koksal, I. (2011). The diagnostic and prognostic significance of soluble urokinase plasminogen activator receptor in Crimean-Congo hemorrhagic fever. J Clin Virol 50, 209-211.
244. Yoshida, E., Ohmura, S., Sugiki, M., Maruyama, M., and Mihara, H. (1995). Prostate-specific antigen activates single-chain urokinase-type plasminogen activator. Int J Cancer 63, 863-865.
245. Yuan, H., Vance, K. M., Junge, C. E., et al. (2009). The serine protease plasmin cleaves the amino-terminal domain of the NR2A subunit to relieve zinc inhibition of the N-methyl-D-aspartate receptors. J Biol Chem 284, 12862-12873.
246. Zhou, A., Huntington, J. A., Pannu, N. S., Carrell, R. W., and Read, R. J. (2003). How vitronectin binds PAI-1 to modulate fibrinolysis and cell migration. Nat Struct Biol 10, 541-544.